LLY
Eli Lilly and Company
LLY has the edge over TLRY overall, supported by lower modeled downside and stronger fundamentals.
TLRY
Tilray Brands, Inc.
TLRY's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TLRY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
TLRY's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TLRY PE Valuation
TLRY has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TLRY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TLRY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TLRY on earnings quality, reporting a profit while its opponent remains loss making.
TLRY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.41 | +$22.79 |
| Q2 2026 | -$1.09 | +$23.51 |
| Q1 2026 | -$15.15 | -$4.65 |
| Q4 2025 | -$23.61 | -$20.61 |
| Q3 2025 | -$24.20 | -$21.50 |
| Q2 2025 | -$24.60 | -$21.30 |
| Q1 2025 | -$10.50 | -$5.50 |
| Q4 2024 | -$3.00 | +$19.80 |
TLRY is still losing money, but far less than before: $1.41 per share over the past year, against $58.23 at its worst in mid-2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TLRY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TLRY on profitability, with a higher operating margin.
TLRY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $257.1M | +23% |
| Q2 2026 | $281.7M | +25% |
| Q1 2026 | $206.7M | +11% |
| Q4 2025 | $217.5M | +3.1% |
| Q3 2025 | $209.5M | +4.7% |
| Q2 2025 | $224.5M | -2.3% |
| Q1 2025 | $185.8M | -1.4% |
| Q4 2024 | $211M | +8.9% |
TLRY's revenue has grown year over year for five quarters in a row: $257M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9.3% | -10 points |
| Q2 2026 | -5.8% | +637 points |
| Q1 2026 | -13% | +396 points |
| Q4 2025 | -10% | +9.8 points |
| Q3 2025 | 1% | +19 points |
| Q2 2025 | -643% | -636 points |
| Q1 2025 | -409% | -366 points |
| Q4 2024 | -20% | +1.5 points |
TLRY's operating margin was −9.3% last quarter, down 10 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TLRY on cash generation, producing positive trailing cash flow while its opponent burns cash.
TLRY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$16.5M | -$15.2M |
| Q2 2026 | -$37.3M | -$18.2M |
| Q1 2026 | -$21.9M | -$1.8M |
| Q4 2025 | -$8.5M | +$37.6M |
| Q3 2025 | -$1.3M | +$40.7M |
| Q2 2025 | -$19.1M | -191% |
| Q1 2025 | -$20.2M | +$4.7M |
| Q4 2024 | -$46.2M | -$9.9M |
TLRY has burned cash in almost every quarter: −$84M over the past year, against −$87M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TLRY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TLRY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +19% | +21.5M shares |
| 1 year | +26% | +27.3M shares |
| 3 years | +93% | +64.2M shares |
| 5 years | +197% | +88.4M shares |
| Available history | +1484% | +125M shares |
TLRY has 133M diluted shares, up 26% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TLRY Net Leverage
TLRY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TLRY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.0 | Oversold |
| Stochastic | 6.8 | Oversold |
TLRY's weekly RSI is 28 (oversold) and its Stochastic is 7 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TLRY PE vs Healthcare Sector
TLRY has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TLRY on trend strength, trading above more of its moving averages.
TLRY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.13 | 20% below |
| 20 week MA | $3.90 | 36% below |
| 50 week MA | $5.89 | 58% below |
| 100 week MA | $7.39 | 66% below |
| 200 week MA | $13.9 | 82% below |
TLRY is in a downtrend: it's below all five of its weekly moving averages, and 82% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TLRY on returns for 2026, with the stronger performance.
TLRY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $162.8 | $85.9 | -47% |
| 2021 | $85.9 | $78.4 | -8.7% |
| 2022 | $78.4 | $27.9 | -64% |
| 2023 | $27.9 | $23.0 | -18% |
| 2024 | $23.0 | $14.3 | -38% |
| 2025 | $14.3 | $9.60 | -33% |
| 2026 YTD | $9.60 | $2.49 | -74% |
TLRY has finished every year since 2020 lower, and it's down 74% so far in 2026.